Biotech entity
All 2 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 2 also mention Chinese biotech industry, the most common co-covered peer. They are better corroborated than the beat average, carrying 6 original sources each against 3.2 for the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 2 also mention Chinese biotech industry, the most common co-covered peer. They are better corroborated than the beat average, carrying 6 original sources each against 3.2 for the same window. The 92-day window averages about 0.2 stories each week. Their average consequence score of 7 runs above the beat's 6.7 for that window. We currently track 2 Biotech stories that mention National Medical Products Administration, published between March 25, 2026 and June 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 52 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering National Medical Products Administration. Shared-story counts are live from our verified record — not editorial picks.
NMPA releases 2025 report
China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Cost advantages quantified
At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Phase II Completion
Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
Record trial count achieved
5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
Pre-surge baseline
Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).
With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Source: Julie Zhang (hk) · Julie Zhang (hk)
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
National Medical Products Administration is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
